Scientific Research Overview

Taurox™ Listing of Scientific Research

Summary of The Immunostimulatory Effects of Taurox SB™

 

Taurox™ Listing of Scientific Research

 

Taurox™ (also known as Taurox SB™) is a new patent protected immuno-therapeutic Adaptive MicroMed™.

Taurox scientific research has six sources:

• Results from University of New Mexico research – Laboratory animals and in vitro testing
• Results from University of Maryland research – Human Cells in Culture
• Independent veterinarians
• The Integrative Medicine Institute, David Riley, M.D., Proving Trial
• Human Clinical Structured Case Investigations – various independent doctors
• Human Clinical Outcome Studies – various independent doctors

Taurox Performance and Scientific Research Documents Available

1. A Review of Sulfur Containing Adaptive MicroMeds™ - Taurox™ and Beta LT® - Molecular Activity, Safety, and Efficacy, Taub, FE and Mayerson, SE, Manuscript in preparation.

2. Data on Fatigue, Allergies and Hepatitis from Structured Case Histories and Clinical Outcome Trials of Taurox™

3. The Immunostimulatory Effects of Taurox SB™, Dunn, T. M., Taub, F. E., Pontzer, C H., Department of Cell Biology and Molecular Genetics, University of Maryland, Submitted for publication 2001

4. Thesis on the Immunostimulatory Effects of Taurox SB™, Dunn, T. M., Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore School of Medicine, 2000. Summary below.

5. In Vitro Cell Culture In Media Containing Beta-Alanyl-Taurine or Carbobenzoxy Beta-Alanyl-Taurine, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 6,323,025 B1, November 27, 2001

6. In Vitro Cell Culture In Media Containing Beta-Alanyl-Taurine or Carbobenzoxy Beta-Alanyl-Taurine, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 6,096,536, August 1, 2000.

7. Therapeutic Use of Vitalethine Modulators in Neoplasis, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 5,578,313, November 26, 1996

8. Therapeutic Use of Vitalethine Modulators in Neoplasia, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 5,370,868, December 4, 1994

9. Vitalethine Modulates Erythropoisis and Neoplasia, Knight, G. D., Laubscher, K. H., Fore, M. L., Clark, Scanlen, T. J., Cancer Research, 1994; 54(21): 5623-35


Taurox Monograph and Toxicology Documents

1. Addendum to Toxicology Monograph on Taurox SB, Rice, S. A., April 1, 2002 (Confidential)

2. Taurox SB Review Of Dr. Susan Rice’s Toxicology Monograph And Response To 4 November 2001 MRC Meeting Report Questions, Hood, R. D., March 29, 2002 (Confidential)

3. Comparison of Toxicity Risks of Five Common Homeopathic Drugs and Taurox SB, Foxman, E. L., October 23, 2001 (Confidential)
4. Proving Report – Taurox SB, Riley, D., Integrative Medicine Institute, 2001 (Confidential)

5. Toxicology Monograph on Taurox SB, Rice, S. A., September 13, 2001 (Confidential)

6. Taurox Monograph Submissions, May 2001 and September 2001 (Confidential)




Summary of The Immunostimulatory Effects of Taurox SB™

Dunn, T. M., Taub, F. E., Pontzer, C. H.

 

Background and Introduction

Taurox™ (also known as Taurox SB) is thought to potentiate the immune response in T cells. Dunn et al. examined the ability of Taurox to modulate the immune system as detected by activation markers, second messenger cascades, proliferation, and cytokine production. The results of these studies gave insight into the potential mechanism of action of Taurox as an immunostimulatory Adaptive MicroMed™.

Taurox Effects

Component of
T-Cell Activation
Taurox
Performance
Results
Calcium Mobilization
Enhanced
Taurox stimulates abrupt and sustained (7 minute) calcium movement in PBMC’s
Similar results: B-Cell (Raji), T-Cell (MOLT-4 & H9), Monocytic cells (HL60)
CD69
Increased
Taurox caused 150% increase in CD-69 for T-Cells
Taurox caused 200% increase in CD-69 for T-Cells HUT-78, MOLT-4
Surface TNF-alpha
Increased
Taurox increased surface TNF Alpha 700% to 130% (varied Taurox levels)
Secreted TNF-alpha
Decreased
Taurox reduced in stimulated cells
Supports Taurox limited toxicity and anti-allergy type effects
IFN-Gamma message & protein
Increased & Decreased
Normal – Taurox increased IFN Gamma 460% to 150%
(varied Taurox levels)
Stimulated – Taurox decreased IFN Gamma 43% to 14%
(varied Taurox levels)
Proliferation with PHA
Enhanced
Taurox stimulates T Cell production 150% - PHA present
Proliferation w/o PHA
Enhanced
Taurox stimulates T Cell production over 200% - PHA not present.

 

Definition of Terms:

Calcium Mobilization = increased activation of calcium movement, a chemical indicator of white blood cell activation.
CD 69 = an early chemical indicator of White Blood Cell activation.
IFN = Interferon, a protein made by immune cells
PBMC = Peripheral Blood Mononuclear Cells, a mixture of WBC’s, immune system cells, including B Cells, T Cells, Monocytic Cells
PHA = a material that stimulates T Cells (T-Cells are a type of WBC) to reproduce.
Surface TNF = TNF which has migrated to the surface of white blood cells.
Secreted TNF = TNF which has released into the cell.
TNF = Tumor Necrosis Factor, protein made by immune cells. Made inside white blood cells and migrates to surface of white blood cells.
WBC = White Blood Cells, primary cells to fight infection.